Background <p>Although most studies of anticancer T-cell immunity focus on αβ T cells, T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with…
V{delta}1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma
Journal for ImmunoTherapy of Cancer | | Herold, N., Bochem, J., Leyens, J., Wingerter, S., Forchhammer, S., Spreuer, J., Deseke, M., Yurttas, C., Nocerino, P., Antunes dos Reis, R., Amaral, T., Wagner, N. B., Thiel, K., Soffel, D., Bieber, K., Terheyden, P., Wesch, D., Oberg, H.-H., Sebens, S., Claassen, M., Königsrainer, A., Garbe, C., Pawelec, G., Meier, F., Löffler, M. W., Weide, B., Prinz, I., Ravens, S., Kordasti, S., Eigentler, T., Wistuba-Hamprecht, K.
Topics: skin-cancer, immunotherapy
Read the full article at Journal for ImmunoTherapy of Cancer